Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

Research output: Contribution to journalArticle

Standard

Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. / Söderlund, Stina; Christiansson, Lisa; Persson, Inger; Hjorth-Hansen, Henrik; Richter, Johan; Simonsson, Bengt; Mustjoki, Satu; Olsson-Strömberg, Ulla; Loskog, Angelica.

In: Leukemia Research, Vol. 50, 01.11.2016, p. 95-103.

Research output: Contribution to journalArticle

Harvard

Söderlund, S, Christiansson, L, Persson, I, Hjorth-Hansen, H, Richter, J, Simonsson, B, Mustjoki, S, Olsson-Strömberg, U & Loskog, A 2016, 'Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli', Leukemia Research, vol. 50, pp. 95-103. https://doi.org/10.1016/j.leukres.2016.09.019

APA

CBE

MLA

Vancouver

Author

Söderlund, Stina ; Christiansson, Lisa ; Persson, Inger ; Hjorth-Hansen, Henrik ; Richter, Johan ; Simonsson, Bengt ; Mustjoki, Satu ; Olsson-Strömberg, Ulla ; Loskog, Angelica. / Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli. In: Leukemia Research. 2016 ; Vol. 50. pp. 95-103.

RIS

TY - JOUR

T1 - Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

AU - Söderlund, Stina

AU - Christiansson, Lisa

AU - Persson, Inger

AU - Hjorth-Hansen, Henrik

AU - Richter, Johan

AU - Simonsson, Bengt

AU - Mustjoki, Satu

AU - Olsson-Strömberg, Ulla

AU - Loskog, Angelica

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background and aims The simultaneous measurement of many proteins is now possible using multiplex assays. In this pilot study we investigated a total of 124 proteins in plasma from chronic myeloid leukemia (CML) patients with the purpose of identifying proteins that are differently expressed at diagnosis and after tyrosine kinase inhibitor (TKI) treatment initiation. Methods Samples were taken from 14 CML patients at diagnosis and after three months of TKI treatment (imatinib or dasatinib). Samples were analyzed by Mesoscale Discovery, Myriad RBM MAP technology and Olink Proseek. Results Multiple plasma proteins were differentially expressed before and after initiation of TKI therapy. Protein patterns demonstrated a possible shift towards Th1-immunity and reduced angiogenic stimuli. Further, some plasma proteins were identified that can be of potential interest to study further for biologic, prognostic or therapeutic significance such as E-selectin, uPAR, growth hormone and carbonic anhydrase IX. Conclusions Plasma proteomics seems feasible and useful in CML patients, both for studying patterns of protein expression and for identifying single proteins differentially expressed before and after treatment. Plasma proteomics may be useful to map disease activity and biological processes. Hence, plasma proteomics can be used to understand drug mechanisms and treatment responses in CML.

AB - Background and aims The simultaneous measurement of many proteins is now possible using multiplex assays. In this pilot study we investigated a total of 124 proteins in plasma from chronic myeloid leukemia (CML) patients with the purpose of identifying proteins that are differently expressed at diagnosis and after tyrosine kinase inhibitor (TKI) treatment initiation. Methods Samples were taken from 14 CML patients at diagnosis and after three months of TKI treatment (imatinib or dasatinib). Samples were analyzed by Mesoscale Discovery, Myriad RBM MAP technology and Olink Proseek. Results Multiple plasma proteins were differentially expressed before and after initiation of TKI therapy. Protein patterns demonstrated a possible shift towards Th1-immunity and reduced angiogenic stimuli. Further, some plasma proteins were identified that can be of potential interest to study further for biologic, prognostic or therapeutic significance such as E-selectin, uPAR, growth hormone and carbonic anhydrase IX. Conclusions Plasma proteomics seems feasible and useful in CML patients, both for studying patterns of protein expression and for identifying single proteins differentially expressed before and after treatment. Plasma proteomics may be useful to map disease activity and biological processes. Hence, plasma proteomics can be used to understand drug mechanisms and treatment responses in CML.

KW - Angiogenesis

KW - Chronic myeloid leukemia

KW - Proteomics

KW - Th1

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84989344889&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.09.019

DO - 10.1016/j.leukres.2016.09.019

M3 - Article

VL - 50

SP - 95

EP - 103

JO - Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis

T2 - Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis

JF - Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis

SN - 1873-5835

ER -